Condition: Coronary Artery Disease · Sponsor: Asan Medical Center
Objectives: To assess the safety of tailored antiplatelet therapy (short DAPT followed by P2Y12 inhibitor alone strategy) in patients who received optimized DES implantation guided by intravascular imaging (IVUS or OCT) Hypothesis: Tailored antiplatelet strategy (short DAPT followed by P2Y12 inhibitor alone) is superior to conventional antiplatelet strategy in terms of clinically relevant bleeding and noninferior for ischemic composite adverse events in patients who received intravascular imaging-guided optimized DES implantation. (Optimized stent evaluated by on-site IVUS/OCT could act as an essential criterion for decision making for tailored antithrombotic strategy)
This description comes directly from the study's public registry record.
Ji Sue Hong, RN · 82 2-2045-3798 · sue5165@naver.com
Pil Hyung Lee, MD · 82 2-3010-3170 · pilmo11@hanmail.net
Always discuss trial participation with your own doctor first.
| Bucheon Sejong Hospital | Bucheon-si, South Korea | Recruiting |
| Dong-A University Hospital | Busan, South Korea | Recruiting |
| Inje University Busan Paik Hospital | Busan, South Korea | Not Yet Recruiting |
| Inje University Haeundae Paik Hospital | Busan, South Korea | Not Yet Recruiting |
| Kosin University Gospel Hospital | Busan, South Korea | Recruiting |
| Gyeongsang National University Changwon Hospital | Changwon, South Korea | Recruiting |
| Kangwon National University Hospital | Chuncheon, South Korea | Recruiting |
| Chungbuk National University Hospital | Chungju, South Korea | Recruiting |
| Daegu Catholic Univ Medical Center | Daegu, South Korea | Not Yet Recruiting |
| Keimyung University Dongsan Medical Center | Daegu, South Korea | Recruiting |
| Kyungpook National University Hospital | Daegu, South Korea | Recruiting |
| Veterans Hospital | Daegu, South Korea | Recruiting |
+ 21 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05418556